1. Home
  2. LTRN vs CTSO Comparison

LTRN vs CTSO Comparison

Compare LTRN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$2.56

Market Cap

38.7M

Sector

Health Care

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.68

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRN
CTSO
Founded
2013
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.7M
45.9M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
LTRN
CTSO
Price
$2.56
$0.68
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$25.00
$5.38
AVG Volume (30 Days)
46.6K
77.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
N/A
$8.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.53
52 Week Low
$2.45
$0.60
52 Week High
$5.74
$1.39

Technical Indicators

Market Signals
Indicator
LTRN
CTSO
Relative Strength Index (RSI) 35.45 N/A
Support Level $2.53 N/A
Resistance Level $3.65 N/A
Average True Range (ATR) 0.20 0.00
MACD -0.01 0.00
Stochastic Oscillator 19.23 0.00

Price Performance

Historical Comparison
LTRN
CTSO

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: